Tag: funding

PUNE, India, June 25, 2025 /PRNewswire/ -- Credence Research, a leading market research and consulting firm has released its most recent research about the...

Guidesly Guides now have a New AI Tool with the Invention of Guidesly's Jack AI™Jack AI Provides the Guidesly Guide a No-Touch, AI Experience...

SKYX Provides Corporate Update

New strategic partnership will accelerate the scale-up of high-impact immunization delivery innovations BRUSSELS, June 25, 2025 /CNW/ - Grand Challenges Canada (GCC), one of the world's...

Bipartisan majorities favor higher not lower taxes on the wealthy, cutting defense spending not increasing it, no cuts to Medicaid, reducing deficit not increasing...

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a chromosome 22 deletion, presenting symptoms like heart defects, immune deficiencies, and developmental delays. Market growth is driven by advancements in diagnostic technologies like next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), enabling early detection and tailored interventions. Despite the lack of a cure, targeted therapies, such as Zynerba Pharmaceuticals' Zygel, are emerging. Increased awareness, research funding, and strategic collaborations are enhancing patient care and shaping a promising future for the 22q11.2 deletion syndrome market.

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a chromosome 22 deletion, presenting symptoms like heart defects, immune deficiencies, and developmental delays. Market growth is driven by advancements in diagnostic technologies like next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), enabling early detection and tailored interventions. Despite the lack of a cure, targeted therapies, such as Zynerba Pharmaceuticals' Zygel, are emerging. Increased awareness, research funding, and strategic collaborations are enhancing patient care and shaping a promising future for the 22q11.2 deletion syndrome market.

NORTH CHICAGO, Ill., June 25, 2025 /PRNewswire/ -- UP Oncolytics, a neuro-oncology biotechnology company based in Milwaukee and a spin-out of the Advocate Aurora Research...

Global Capacity for 7nm and Below to Reach 1.4 Million Wafers Per Month by 2028  MILPITAS, Calif., June 25, 2025 /PRNewswire/ -- SEMI, the industry...

Global Capacity for 7nm and Below to Reach 1.4 Million Wafers Per Month by 2028  MILPITAS, Calif., June 25, 2025 /CNW/ -- SEMI, the industry...

Global Capacity for 7nm and Below to Reach 1.4 Million Wafers Per Month by 2028  MILPITAS, Calif., June 25, 2025 /PRNewswire/ -- SEMI, the industry...

Global Capacity for 7nm and Below to Reach 1.4 Million Wafers Per Month by 2028  MILPITAS, Calif., June 25, 2025 /PRNewswire/ -- SEMI, the industry...

zerohash further expands USDC accessibility with integration of native USDC on World Chain

zerohash further expands USDC accessibility with integration of native USDC on World Chain

Ignis Energy, a geothermal exploration and development company, today announced the final close of its Series A funding round, securing $13.6 million.